Pharvaris NV
PHVS
Detailliertes Diagramm anzeigen
26.420USD
+1.280+5.09%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.72BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+5.09%
5 Tage
-2.33%
1 Monat
+9.85%
6 Monate
+24.45%
Seit Jahresbeginn
-4.79%
1 Jahr
+44.69%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Kein Aktien-Score verfügbar aufgrund unzureichender Daten.
Pharvaris NV Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Gesamteinnahmen
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Pharvaris NV Informationen
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
BörsenkürzelPHVS
UnternehmenPharvaris NV
CEOModig (Berndt B.A.E)
Websitehttps://pharvaris.com/
Verwandte Finanzinstrumente
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Beliebte Symbole
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70115.700
+145.570 (+0.21%)
282.580
+22.390 (+8.61%)
2076.340
+24.610 (+1.20%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
